JP2023540464A5 - - Google Patents
Info
- Publication number
- JP2023540464A5 JP2023540464A5 JP2023512663A JP2023512663A JP2023540464A5 JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5 JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023540464 A5 JP2023540464 A5 JP 2023540464A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- sequence
- acid sequence
- poly
- codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010706505.5A CN113952473A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| CN202010706658.XA CN113952474A (zh) | 2020-07-21 | 2020-07-21 | 用于治疗眼部疾病的组合物和方法 |
| PCT/IB2021/000498 WO2022018516A1 (en) | 2020-07-21 | 2021-07-20 | Composition and method for treating eye diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540464A JP2023540464A (ja) | 2023-09-25 |
| JP2023540464A5 true JP2023540464A5 (enExample) | 2024-07-26 |
| JP7842082B2 JP7842082B2 (ja) | 2026-04-07 |
Family
ID=79728536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512663A Active JP7842082B2 (ja) | 2020-07-21 | 2021-07-20 | 眼疾患を処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295243A1 (enExample) |
| EP (1) | EP4185333A4 (enExample) |
| JP (1) | JP7842082B2 (enExample) |
| CN (1) | CN116323949A (enExample) |
| AU (1) | AU2021313839A1 (enExample) |
| CA (1) | CA3186830A1 (enExample) |
| WO (1) | WO2022018516A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2025506383A (ja) * | 2022-02-02 | 2025-03-11 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法 |
| JP2026509829A (ja) * | 2023-03-10 | 2026-03-25 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 昆虫細胞における組換えアデノ随伴ウイルス（ｒＡＡＶ）産生 |
| IL326320A (en) * | 2023-08-03 | 2026-04-01 | Arcum Vision Inc | Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2575490A1 (en) * | 2004-08-03 | 2006-02-16 | Frank Notka | Method for modulating gene expression by altering the cpg content |
| DE102004037611B4 (de) * | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
| CN105026433B (zh) * | 2014-01-24 | 2018-10-19 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| CA2977355A1 (en) * | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| CN117531025A (zh) * | 2016-06-16 | 2024-02-09 | 阿德夫拉姆生物技术股份有限公司 | 使用aav2变体和阿柏西普治疗amd |
| MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
| US11766489B2 (en) * | 2017-11-27 | 2023-09-26 | 4D Molecular Therapeutics, Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| CA3086045A1 (en) * | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| MX2020010465A (es) * | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| WO2020102645A1 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus for treating pompe disease |
| CN114375195A (zh) * | 2019-09-11 | 2022-04-19 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| KR20230088630A (ko) * | 2020-10-16 | 2023-06-20 | 자이로스코프 테라퓨틱스 리미티드 | 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도 |
| AU2022253065A1 (en) * | 2021-04-09 | 2023-09-28 | Avirmax Biopharma Inc. | Compositions and methods for ocular transgene expression |
| EP4330411B1 (en) * | 2021-04-27 | 2026-03-18 | 4D Molecular Therapeutics Inc. | Compositions and methods for treatment of ocular disease associated with angiogenesis |
| EP4349852A4 (en) * | 2021-05-28 | 2025-09-03 | Shanghai Regenelead Therapies Co Ltd | RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING A VARIANT CAPSID, AND ITS APPLICATION |
-
2021
- 2021-07-20 AU AU2021313839A patent/AU2021313839A1/en active Pending
- 2021-07-20 CN CN202180064547.6A patent/CN116323949A/zh active Pending
- 2021-07-20 EP EP21845723.2A patent/EP4185333A4/en active Pending
- 2021-07-20 JP JP2023512663A patent/JP7842082B2/ja active Active
- 2021-07-20 CA CA3186830A patent/CA3186830A1/en active Pending
- 2021-07-20 WO PCT/IB2021/000498 patent/WO2022018516A1/en not_active Ceased
-
2023
- 2023-01-20 US US18/157,599 patent/US20230295243A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3717636B1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| EP3827812B1 (en) | Adeno-associated virus virions with variant capsid and methods of use thereof | |
| US10494619B2 (en) | High isomerohydrolase activity mutants of human RPE65 | |
| TW202313096A (zh) | 衣殼變異的重組腺相關病毒及其應用 | |
| US20240091383A1 (en) | Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy | |
| AU2021236481A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| JP2021522842A (ja) | 肝臓を標的とするアデノ随伴ウイルスベクター | |
| CN110650733A (zh) | 经过修饰的aav衣壳和其用途 | |
| EP3978614A2 (en) | Single-vector gene construct comprising insulin and glucokinase genes | |
| EP2699270A2 (en) | Adeno-associated virus virions with variant capsid and methods of use thereof | |
| JP2021534814A5 (enExample) | ||
| JP2023509443A5 (enExample) | ||
| JP2024105661A (ja) | 眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療 | |
| CN118853712A (zh) | 编码抗vegf蛋白的核酸、多核苷酸表达盒及重组腺相关病毒 | |
| JP2023535232A5 (enExample) | ||
| WO2016037931A1 (en) | Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases | |
| EP4516913A1 (en) | Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced | |
| WO2025214408A9 (en) | Optogenetic modulation for vision restoration | |
| CN117070541A (zh) | 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒 | |
| KR20010040309A (ko) | 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법 | |
| HK40110810A (en) | A method for gene regulation and application thereof | |
| RU2024110159A (ru) | Генная терапия фратаксином | |
| CN117070540A (zh) | 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒 | |
| CN121406675A (zh) | 一种新型基因治疗药物 | |
| CN117587028A (zh) | 编码抗vegf的抗体或抗原结合片段的多核苷酸表达盒及质粒 |